(Q38175354)

30 August 2017

Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

Brian Godman

5

0 references

author name string

Ana Luísa Caires de Souza

1

1 reference

30 August 2017

Francisco de Assis Acurcio

2

1 reference

30 August 2017

Augusto Afonso Guerra Júnior

3

1 reference

30 August 2017

Renata Cristina Rezende Macedo do Nascimento

4

1 reference

30 August 2017

Leonardo Maurício Diniz

6

1 reference

30 August 2017

1 February 2014

1 reference

Applied Health Economics and Health Policy

30 August 2017

1 reference

30 August 2017

12

1 reference

30 August 2017

19-32

1 reference

30 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s40258-013-0073-6

30 August 2017

0 references

cites work

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Changes in the utilization of venlafaxine after the introduction of generics in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Novel insulin analogues and its mitogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Does diabetes therapy influence the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

The insulin dilemma in resource-limited countries. A way forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

International variability in the reimbursement of cancer drugs by publically funded drug programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0073-6

10.1007/S40258-013-0073-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference